WASHINGTON, D.C. - A committee convened by the National Institutes of Health (NIH) has found that treatment for the hepatitis C virus (HCV) has significantly improved during the past five years.
Sustained response rates have reportedly increased from 15 percent to 50 percent from treatment with combination therapies. Specifically, interferon and the antiviral drug ribavirin have improved the treatment of patients dramatically.
HCV, which is the leading cause of liver disease and liver cancer, has infected an estimated 4 million Americans.
Information from www.azcentral.com
Evolving Symptomatology: Respiratory Viruses in the Era of COVID-19 Variants
September 27th 2023As COVID-19 restrictions eased up, other respiratory viruses began circulating alongside SARS-CoV-2. It's crucial to identify cases and understand the symptoms of these infections to track the evolution of the virus and what health care workers should look out for.
Poll: What Minimum Educational Requirement Should Infection Preventionists Have?
September 25th 2023Many infection preventionists (IPs) disagree on the minimum requirement to have the IP position. Let Infection Control Today know your opinion. Answer this poll, and send your thoughts to Senior Editor Tori Whitacre Martonicz at tmartonicz@mjhlifesciences.com.
How to Prepare For Possible “Tripledemic” of RSV, Influenza, and SARS-CoV-2
September 25th 2023The interaction between the respiratory viruses SARS-CoV-2, influenza, and RSV, poses ongoing challenges. Personal protective measures, testing, and vaccination are critical components of our strategy to mitigate the impact of these viruses.
2 Clarke Drive
Cranbury, NJ 08512